VK-2019

• UNSPSC Description:

  VK-2019 is an oral active, selective EBNA1((Epstein-Barr Nuclear Antigen 1) inhibitor and can be used for study of EBV-associated carcinomas[1].

• Target Antigen:

  EBV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/vk-2019.html

• Purity:

  99.97

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  OC(C1=C(C(C#CC2=CC=C(C=C2)COC3CCOCC3)=CC=C1)C4=CC5=C(C=C4)NC=C5)=O

• Molecular Weight:

  451.51

• References & Citations:

  [1]Davis MT, et al. Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK-2019, a selective EBNA1 inhibitor. Biomed Chromatogr. 2024;38(2):e5775.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 2

• CAS Number:

  2044520-06-9